# Developmental Therapeutics Program

## One Dose Mean Graph

| | | |
|---|---|---|
| **NSC:** 765720 / 1 | **Conc:** 1.00E-5 Molar | **Test Date:** Jun 11, 2012 |
| **Experiment ID:** 1206OS93 | | **Report Date:** Oct 12, 2012 |

| Panel/Cell Line | Growth Percent |
|---|---|
| Leukemia | |
| CCRF-CEM | 84.32 |
| HL-60(TB) | 108.96 |
| K-562 | 91.30 |
| MOLT-4 | 85.75 |
| RPMI-8226 | 70.73 |
| Non-Small Cell Lung Cancer | |
| A549/ATCC | 88.23 |
| HOP-62 | 70.66 |
| HOP-92 | 82.51 |
| NCI-H226 | 78.99 |
| NCI-H23 | 90.48 |
| NCI-H322M | 91.18 |
| NCI-H460 | 88.01 |
| NCI-H522 | 74.09 |
| Colon Cancer | |
| COLO 205 | 91.29 |
| HCC-2998 | 95.65 |
| HCT-116 | 74.00 |
| HCT-15 | 86.04 |
| HT29 | 94.04 |
| KM12 | 89.04 |
| SW-620 | 84.47 |
| CNS Cancer | |
| SF-268 | 91.63 |
| SF-539 | 76.61 |
| SNB-19 | 88.67 |
| SNB-75 | 39.33 |
| U251 | 90.37 |
| Melanoma | |
| LOX IMVI | 76.38 |
| MALME-3M | 109.82 |
| M14 | 85.80 |
| MDA-MB-435 | 102.90 |
| SK-MEL-2 | 95.52 |
| SK-MEL-28 | 97.01 |
| SK-MEL-5 | 86.71 |
| UACC-257 | 113.18 |
| UACC-62 | 65.14 |
| Ovarian Cancer | |
| IGROV1 | 119.23 |
| OVCAR-3 | 101.68 |
| OVCAR-4 | 82.76 |
| OVCAR-5 | 79.92 |
| OVCAR-8 | 76.48 |
| NCI/ADR-RES | 73.37 |
| SK-OV-3 | 83.81 |
| Renal Cancer | |
| 786-0 | 94.19 |
| A498 | 81.85 |
| ACHN | 84.29 |
| CAKI-1 | 72.21 |
| RXF 393 | 87.11 |
| SN12C | 84.60 |
| TK-10 | 91.07 |
| UO-31 | 54.89 |
| Prostate Cancer | |
| PC-3 | 71.99 |
| DU-145 | 100.47 |
| Breast Cancer | |
| MCF7 | 86.07 |
| MDA-MB-231/ATCC | 73.15 |
| HS 578T | 64.39 |
| BT-549 | 82.80 |
| T-47D | 87.85 |
| MDA-MB-468 | 69.73 |
| Mean | 84.96 |
| Delta | 45.63 |
| Range | 79.90 |

**Mean Growth Percent - Growth Percent**